Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 3 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Breast Neoplasms 149Lymphoma 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Large B-Cell, Diffuse 46Leukemia 44Lymphoma, Follicular 39Lymphoma, Non-Hodgkin 35Multiple Myeloma 33Leukemia, Lymphocytic, Chronic, B-Cell 28Leukemia, Myeloid, Acute 25Burkitt Lymphoma 24Neuroblastoma 21Lymphoma, Large-Cell, Immunoblastic 16Hodgkin Disease 16Lymphoma, Mantle-Cell 14Neoplasms 13Triple Negative Breast Neoplasms 12Lymphoma, B-Cell, Marginal Zone 11Sarcoma 10Inflammatory Breast Neoplasms 10Rhabdomyosarcoma 8Recurrence 8Neoplasms, Plasma Cell 8Myelodysplastic Syndromes 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Graft vs Host Disease 8Lymphoma, T-Cell, Peripheral 7Lymphoma, Large-Cell, Anaplastic 7Leukemia, Biphenotypic, Acute 7Lung Neoplasms 6

Interventions

Oxaliplatin 10Fluorouracil 7Leucovorin 6Gemcitabine 6Docetaxel 6Capecitabine 6Paclitaxel 5Cisplatin 5zolbetuximab 4Ramucirumab 3Pemetrexed 3Drug Therapy 3Carboplatin 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3regorafenib 2pembrolizumab 2Vinorelbine 2Surgical Procedures, Operative 2Radiotherapy 2Nivolumab 2Neoadjuvant Therapy 2Cyclophosphamide 2Chemoradiotherapy 2Bevacizumab 2Afatinib 2vandetanib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Adenocarcinoma × Cyclophosphamide × Clear all
NCT00887536 2022-04-20

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NSABP Foundation Inc

Phase 3 Completed
1,613 enrolled
Breast

Adenocarcinoma, Breast Diseases, Breast Neoplasms, Carcinoma

NCT00140075 2011-05-26

Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

Pfizer

Phase 3 Completed
606 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡